New Hampshire: (603) 828-0100
New Patient Referrals: 1-833-826-6327

Below is a list of current clinical trials open to enrollment at New England Cancer Specialists. Trials can open and close very quickly, depending on the phase of the study, responses from patients already enrolled, or FDA requests.

We try to have a trial available in every disease area, but this isn’t always possible. If you don’t see a study that might be right for you, please ask your doctor or nurse.

For a full list of clinical trials across the U.S., visit ClinicalTrials.gov.

If you have questions or wish to speak with someone from our research department, contact us.

Bladder

Bladder, Keynote-905                                                                                                  Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer Learn more

Bladder, T-1-19 (MK7902-011)
A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011).  Learn more

Bladder, T-2-19 (MK3475-866)
A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer. Learn more

 

Breast

Breast, CB-1-21 (Checkmate 7FL)                                                                                      A Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer Learn more

Breast, EA1181 (CompassHER2-pCR)
Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)

Breast, S1418
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.

Genomics

Genomics, EAY131 (MATCH)
Molecular Analysis for Therapy Choice. Learn more

 

Liver

Liver, DU-3-20 (WO41535)
A Phase III, Multicenter, Randomized, Open-Label Study of Atezolizumab (ANTI-PD-L1 Antibody) Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellualar Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

Lung

Lung, (T-1-21) Relativity                                                                                                A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) Learn more

Lung, (T-4-20) TH-138                                                                                                   A Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked Learn more

Lung, ECOG E4512
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein. Learn more

Lung, EV-2-19 (MRT516-005)
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy.

Lung, GO41854 Skyscraper03 (T-2-20)‚Äč
A Phase III, Open-label, Randomized Study of Atezolizumab and Tiragolumab Compared with Durvalumab in Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer who have not Progressed After Concurrent Platinum-based Chemoradiation

Melanoma

Melanoma, EA6141                                                                                                           A Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma Learn more

Pancreatic

Pancreatic, DU-1-20 (D-US-60010-001)
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas

NECS Providers
For more information on these clinical trials, visit (log-in required): NECS Clinical Trials